Pharma R&D in Canada on the decline
This article was originally published in Scrip
Executive Summary
Spending on pharmaceutical research and development (R&D) has continued to decline in Canada, says the latest annual report from the Patented Medicine Prices Review Board (PMPRB), which is tasked to look at pharma trends and ensure drug prices are not excessive.